Clinical trials: Liver Cell Carcinoma
Hepatocellular Carcinoma
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
This study will test the hypothesis that a novel combination of three drugs (sorafenib, sonidegib, and irinotecan), in conjunction with individually optimized doses, can be safely administered and lead to improved clinical…
- Trial name
- NCT05669339
- Testing
- Irinotecan, Sonidegib, Sorafenib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Florida
Hepatocellular Carcinoma (HCC)
Streamlined Resin Y90 Radiation Segmentectomy for Small HCC
This single-arm feasibility study evaluating the safety and efficacy of streamlining Yttrium-90 (Y90) radioembolization workflow for patients with small Hepatocellular Carcinoma (\<5cm) that have no aggressive features on…
- Trial name
- One&Done (NCT06618300)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Solid Tumor, Adult
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
This is a Phase 1 dose-finding study of FT538 in combination with monoclonal antibodies.
- Trial name
- NCT05069935
- Testing
- FT538, Cyclophosphamide, Fludarabine
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Fate Therapeutics
Hepatocellular Carcinoma, SBRT
SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular Carcinoma
This is a Phase II , Open-label , Investigator-initiated Trail of SBRT in Combination With Adbelimumab and Apatinib in Patients With Hepatocellular Carcinoma(HCC).This study aims to evaluate the safety and efficacy of SBRT in…
- Conditions
- Hepatocellular Carcinoma, SBRT, Immune Checkpoint Blockade, Tyrosine Kinase Inhibitor
- Trial name
- NCT06538935
- Testing
- adbelimumab, SBRT, apatinib
- Volunteers
- 80 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma Non-resectable
Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy
Patients with locally advanced unresectable or metastatic hepatocellular carcinoma (HCC) who progressed after prior systemic therapy (targeted ± immunotherapy) are enrolled. Primary endpoint: objective response rate (ORR).
- Trial name
- NCT07192848
- Testing
- Adebrelimab + Apatinib
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Song Peng
Hepatocellular Carcinoma
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Transarterial chemoembolization (TACE) based on drug-eluting beads (DEB-TACE) is widely used for unresectable hepatocellular carcinoma (HCC). However, the long-term survival is still low after DEB-TACE treatment.
- Trial name
- NCT04229355
- Testing
- DEB-TACE plus Sorafenib, DEB-TACE plus Lenvatinib, DEB-TACE plus PD-1 inhibitor
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Resectable Hepatocellular Carcinoma
Tislelizumab Monotherapy or Combined With Lenvatinib as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma.
This is a phase II prospective study to evaluate the safety and efficacy of Tislelizumab monotherapy or combined with lenvatinib as neoadjuvant therapy for resectable hepatocellular carcinoma.
- Trial name
- NCT05807776
- Testing
- Tislelizumab, Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma (HCC)
Study of BGB-A317 in Participants With Previously Treated Unresectable HCC
This study investigated the efficacy, safety, and pharmacokinetics of the anti-PD-1 monoclonal antibody BGB-A317 in participants with previously treated hepatocellular unresectable carcinoma.
- Trial name
- NCT03419897
- Testing
- Tislelizumab
- Where
- 54 sites in China, France and 6 more
- Volunteers
- 249 people
- Sponsor
- BeiGene
HepatoCellular Carcinoma, Cirrhosis
Mutational Landscape in Hepatocellular Carcinoma
The MUTHEC project aims to describe the mutational and transcriptomic landscape of HCC treated by curative treatments (resection, radio frequency ablation, transplantation) as well as advanced HCC together with the analysis of…
- Trial name
- MUTHEC (NCT03071458)
- Where
- France
- Volunteers
- 808 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Viral Hepatitis B, Viral Hepatitis D
Replicor Compassionate Access Program
The goal of this compassionate access program is to provide early access to REP 2139-Mg for patients with HBV mono-infection or HBV / HDV co-infection who either have advanced (decompensated) cirrhosis or who have failed to…
- Conditions
- Viral Hepatitis B, Viral Hepatitis D, Cirrhosis, Liver, Decompensated Cirrhosis
- Trial name
- RCAP (NCT05683548)
- Testing
- REP 2139-Mg, Tenofovir Disoproxil Fumarate, Pegylated interferon alpha2a
- Where
- 13 sites in Austria, France and 3 more
- Sponsor
- Replicor Inc.
Hepatocellular Carcinoma, Liver Cancer
Early Detection of Liver Cancer by QUS
Worldwide, liver cancers are the third most common cause of cancer mortality. Even when liver cancer is suspected by blood tests, imaging is required to determine the location, size, and extent of disease.
- Trial name
- QUS in HCC (NCT06345508)
- Testing
- Quantitative Ultrasound, B-mode Ultrasound, Magnetic Resonance Imaging
- Where
- Canada
- Volunteers
- 328 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Hepatocellular Carcinoma, Cirrhosis
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Immunotherapy can safely downstage patients and achieve durable systemic disease control to improve clinical outcomes in HCC patients undergoing liver transplant.
- Conditions
- Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension
- Trial name
- NCT05027425
- Testing
- Durvalumab, Tremelimumab, Liver Transplant
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- University of Cincinnati
Hepatocellular Carcinoma
Study of Anti-tumour Effects and Safety of Prolarix™ in Hepatocellular Carcinoma
This an open-label study designed to evaluate the anti-tumour activity and safety of Prolarix in subjects with advanced hepatocellular carcinoma.
- Trial name
- NCT00746590
- Testing
- Prolarix (tretazicar co-administered with caricotamide)
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- BTG International Inc.
Liver Neoplasms, Liver/Hepatobiliary Cancer
CE-IOUS Impact on Surgical Strategy of Liver Tumours and Liver Metastases
Contrast-enhanced intraoperative ultrasound (CE-IOUS) plays an increasingly important role in the surgical therapy planning of primary liver lesions as well as liver metastases.
- Conditions
- Liver Neoplasms, Liver/Hepatobiliary Cancer, Colorectal Cancer Metastatic, Metastases
- Trial name
- NCT05261113
- Testing
- CE-IOUS
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University of Regensburg
Hepatocellular Carcinoma
Identification and Prognostic Value of Key Genes in Hepatocellular Carcinoma
To explore the key genes of human and mouse hepatocellular carcinoma, identify the key genes and prognostic markers, and develop small molecule drugs targeting the key genes to treat hepatocellular carcinoma.
- Trial name
- NCT05759858
- Testing
- None of intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Hepatocellular Carcinoma, Carcinoma
Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC
The purpose of this study is to evaluate the efficacy of sorafenib in combination with low dose cisplatin /fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma.
- Conditions
- Advanced Hepatocellular Carcinoma, Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasms
- Trial name
- NCT01214343
- Testing
- Sorafenib with Low-dose FP, Sorafenib
- Where
- 30 sites in Japan
- Volunteers
- 190 people
- Sponsor
- Ministry of Health, Labour and Welfare, Japan
Hepatocellular Carcinoma
Genetic Studies in Liver Cancer Patients
Hepatocellular carcinoma (HCC) is one the most common malignancies in the world, especially in sub-Saharan Africa and Southeast Asia. Since 1984, it has been the leading cause of cancer death in Taiwan.
- Trial name
- NCT00172640
- Where
- Taiwan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
A Phase-II Trial of ZIO 101 in Advanced Hepatocellular Carcinoma
The study of safety of a new organic arsenic compound in the treatment of advanced hepatocellular carcinoma
- Trial name
- NCT00423306
- Testing
- Darinaparsin
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Alaunos Therapeutics
Lung Cancer, Breast Cancer
Measuring and Improving the Safety of Test Result Follow-Up
Improving communication is foundational to improving patient safety. Electronic health records (EHRs) can improve communication, but also introduce unique vulnerabilities.
- Conditions
- Lung Cancer, Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT04166240
- Testing
- SAFER TRACKS Intervention
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- VA Office of Research and Development
Hepatocellular Carcinoma
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
To compare The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) for Patients With Hepatocellular Carcinoma And Microvascular Invasion (MVI) After Hepatectomy.
- Trial name
- NCT03192618
- Testing
- adjuvant transarterial chemoinfusion (TAI), mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
- Where
- China
- Volunteers
- 290 people
- Sponsor
- Sun Yat-sen University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.